|
| Press Releases |
|
 |
|
| Wednesday, December 20, 2023 |
|
|
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that, OT-703 (ILUVIEN(R), fluocinolone intravitreal implant), an injectable more info >> |
|
| Thursday, August 24, 2023 |
|
|
Ocumension Therapeutics Announces 2023 Interim Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its interim results for the six months ended 30 June 2023 ("the Period") today. more info >> |
|
| Thursday, March 30, 2023 |
|
|
Ocumension Therapeutics Announces 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its annual results for the year ended 31 December 2022 today. more info >> |
|
| Monday, March 13, 2023 |
|
|
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that the Company's ordinary shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on March 13, 2023. more info >> |
|
| Tuesday, February 14, 2023 |
|
|
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, is pleased to announce that it is anticipated that the Company will record a significant increase in its revenue and gross profit for the year ended 31 December 2022 (the "Year 2022"). more info >> |
|
| Friday, February 3, 2023 |
|
|
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202 |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully. more info >> |
|
| Wednesday, February 1, 2023 |
|
|
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that OT-101 (0.01% atropine sulfate eye drop) more info >> |
|
| Monday, January 30, 2023 |
|
|
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively |
| Ocumension Therapeutics (1477.HK) is pleased to announce that Mr. Tim RUAN and Mr. WANG Chong have been appointed as Chief Financial Officer and Head of Investor Relations respectively of the Group. more info >> |
|
| Saturday, March 20, 2021 |
|
|
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results |
| The Chinese ophthalmology platform company, Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended 31 December 2020 today. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Reach Secures Major Investment to Accelerate Its Global Expansion and Fuel Enterprise Merchant Growth
Feb 20, 2025 23:00 HKT/SGT
|
|
|
HKTDC strengthens local competitiveness and global connections
Feb 20, 2025 22:09 HKT/SGT
|
|
|
Explore Cutting-Edge Cybersecurity Solutions at Exito's 25th Cyber Security Summit 
Feb 20, 2025 17:06 HKT/SGT
|
|
|
Prioritise Self-Love and Self-Care This Year For A Better You
Feb 20, 2025 17:00 HKT/SGT
|
|
|
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 20, 2025 13:29 JST
|
|
|
New HKTDC Chairman appointed
Feb 19, 2025 23:44 HKT/SGT
|
|
|
Champion REIT Announces 2024 Annual Results
Feb 19, 2025 23:08 HKT/SGT
|
|
|
NEC X & Carbide Ventures Partner To Rapidly Accelerate Early-Stage Startups
Feb 19, 2025 20:16 JST
|
|
|
Mitsubishi Power Advances Bahrain's Industrial Growth with Completion of Alba's Power Station 5 Block 4 Combined Cycle Power Plant Project
Feb 19, 2025 16:54 JST
|
|
|
GA-ASI and CAE Sign Long-Term Agreement to Develop the Next Generation MQ-9B SkyGuardian(R) Mission Trainer
Feb 19, 2025 15:00 HKT/SGT
|
|
|
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook
Feb 19, 2025 14:42 HKT/SGT
|
|
|
Nissin Foods (Hong Kong) Charity Fund Supports Elite Athletes from The Education University of Hong Kong for the Third Consecutive Year
Feb 19, 2025 14:02 HKT/SGT
|
|
|
TrustCSI 3.0 Navigates the 'Belt and Road' and Empowers Global Enterprise's Digital Journey
Feb 19, 2025 12:41 HKT/SGT
|
|
|
GoDaddy Airo: An AI-Powered Revolutionary Solution for Asian Entrepreneurs and Small Business Owners
Feb 19, 2025 10:18 HKT/SGT
|
|
|
Honda Reveals Specification for its Next-generation Fuel Cell Module
Feb 19, 2025 11:07 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
